Text Size
25 studies found for:    Arnold-Chiari Malformation

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
Arnold-Chiari Malformation (25 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Genetic Analysis of the Chiari I Malformation
Conditions: Syringomyelia;   Type I Arnold Chiari Malformation
Intervention:
2 Completed Establishing the Physiology of Syringomyelia
Conditions: Arnold Chiari Deformity;   Hydrocephalus;   Syringomyelia
Intervention:
3 Completed Duragen Versus Duraguard in Chiari Surgery
Condition: Chiari Malformation
Interventions: Procedure: Duraplasty with Duragen;   Procedure: Duraplasty with Duraguard
4 Recruiting A Prospective Natural History Study of Patients With Syringomyelia
Conditions: Syringomyelia;   Arnold Chiari Deformity
Intervention:
5 Active, not recruiting Magnetic Resonance Imaging (MRI) and Quantitative MR Cerebral Spinal Fluid (CSF) Flow Studies in Craniovertebral Junction Anomalies
Condition: Chiari Malformations
Intervention: Procedure: Dynamic cervical MRI
6 Recruiting Dural Graft Equivalent Comparison Trial
Condition: Chiari Malformation
Intervention: Procedure: decompression of Chiari malformation
7 Enrolling by invitation Chiari Study Looking at Use of Duragen Versus Duraguard
Condition: Chiari Malformation Type I
Intervention:
8 Recruiting Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
Condition: Venous Leg Ulcers
Interventions: Biological: HP802-247;   Biological: Vehicle
9 Completed Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
Condition: Actinic Keratosis
Intervention: Drug: PEP005 Topical gel
10 Completed
Has Results 		Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
Condition: Hypogonadism
Intervention: Drug: testosterone matrix transdermal system
11 Completed Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch
Condition: Healthy
Intervention: Drug: testosterone
12 Completed
Has Results 		Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type
Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine 4.6 mg/24 h (5 cm^2);   Drug: Rivastigmine 9.5 mg/24 h (10 cm^2);   Drug: Rivastigmine 13.3 mg/24 h (15 cm^2);   Drug: Placebo
13 Completed A 24 Week Open-Label Extension to Study CENA713DUS44
Condition: Alzheimer's Disease
Interventions: Drug: ENA713;   Drug: Rivastigmine transdermal patch 15 cm2
14 Recruiting The Genetics of Chiari Type I Malformation
Condition: Chiari Type I Malformation
Intervention:
15 Recruiting Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects
Condition: Articular Cartilage Lesion of the Femoral Condyle
Interventions: Drug: co.don chondrosphere®;   Procedure: Microfracture
16 Completed
Has Results 		Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Condition: Keratosis
Intervention: Drug: imiquimod cream
17 Completed Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects
Condition: Healthy
Intervention: Drug: Rotigotine transdermal patch
18 Completed
Has Results 		Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body
Condition: Healthy Volunteers
Intervention: Drug: Rotigotine transdermal patch
19 Completed
Has Results 		A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine transdermal patch
20 Recruiting Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis
Condition: Actinic Keratosis
Interventions: Drug: Ingenol mebutate gel;   Drug: placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
† Indicates status has not been verified in more than two years